A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

MicroPort Orthopedics Advances Medical Education Through Innovative Technologies and Regional Centers of Excellence

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, has reimagined its approach to medical education through new technologies, strategic partnerships, and regionally based education centers of excellence.

Committed to providing comprehensive education and training opportunities for all of its products, MicroPort Orthopedics is partnering with innovative technology companies such as Osso VR to increase the amount of digital training opportunities. By working with surgeons in key markets globally to supply educational content, MicroPort provides orthopedic surgeons the information and resources they need to help patients achieve Full Function, Faster⁹.

MicroPort Orthopedics partnered with Osso VR, a validated Virtual Reality (VR) surgical training platform, to launch a VR training module for MicroPort Orthopedics’ SuperPATH® Hip Technique and Evolution® Medial-Pivot Knee System.

Osso VR currently has the world’s largest virtual reality surgical training library. With the VR curriculum, surgeons can train and assess themselves on the intuitive workflow of the procedure at their own pace, allowing them to gain proficiency in these high-value techniques. “We’re committed to improving outcomes for patients through democratized access to high-value systems like SuperPATH® and Evolution®.

This partnership with MicroPort Orthopedics increases access to a wider library of surgical techniques while also supporting controlled, high-quality outcomes for patients,” said Justin Barad, MD, Co-Founder and CEO of Osso VR.In addition to offering an enhanced VR training experience, MicroPort Orthopedics has expanded its global Medical Education services through a recently developed program utilizing regional Centers of Excellence to deliver a holistic approach to education and training. These key locations, hosted by a local surgeon expert, provide an extensive learning pathway for surgeons to be educated on key MicroPort products, programs and technologies.

This learning pathway includes: educational presentations, online learning, virtual reality training, in-person cadaveric labs and mentor opportunities with the global surgeon faculty. Key facilities are strategically located across North America, with more locations in development around the world. This program launched in late February of 2021, when Dr. Andrew Ajluni hosted the first Center of Excellence event at Premiere ASC in Troy, Michigan, leading a successful educational lab about MicroPort Orthopedics’ latest tissue sparing portal-assisted hip approach, Anterior Path®.

“With innovative solutions such as the Evolution® Medial-Pivot Knee, and our tissue sparing surgical techniques such as SuperPath® and Anterior Path®, we’re on the verge of a massive paradigm shift in orthopedic procedures that help patients achieve full functionality and recover faster,” said Benny Hagag, President and CEO of MicroPort Orthopedics. “We’re striving to remove any barriers to adopting innovative techniques that can achieve better outcomes for patients, and partnerships are a significant element to this goal. We’re excited to work with other innovative companies such as Osso VR, and expert surgeons around the globe to make these products and solutions accessible to all orthopedic surgeons.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy